11.03.2024 13:28:54

Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts

(RTTNews) - Merck (MRK) announced the completion of the acquisition of Harpoon Therapeutics, Inc. (HARP). Harpoon is now a wholly-owned subsidiary of the company. Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. The impact of the transaction on expected full-year non-GAAP EPS is approximately $0.26 per share, which was included in full-year 2024 financial outlook issued on February 1, 2024.

Harpoon's lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer and neuroendocrine tumors.

For More Such Health News, visit rttnews.com.

Analysen zu Merck Co.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Merck Co. 97,00 0,21% Merck Co.